10-05-2025
Barclays Remains a Buy on 4D Molecular Therapeutics (FDMT)
In a report released on May 8, Gena Wang from Barclays maintained a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), with a price target of $38.00. The company's shares closed yesterday at $3.08.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Wang is a 3-star analyst with an average return of 2.3% and a 39.26% success rate. Wang covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Legend Biotech.
4D Molecular Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.14, implying a 975.97% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $26.00 price target.
Based on 4D Molecular Therapeutics' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1 thousand and a GAAP net loss of $49.67 million. In comparison, last year the company had a GAAP net loss of $32.28 million
